The SELECT trial fundamentally changed how we think about weight loss medications. Before SELECT, GLP-1 drugs were purely weight loss tools. After SELECT, one of them — semaglutide — became a cardiovascular medication too. Here's what the trial showed, what it means for patients, and where the research is heading next.
What Was the SELECT Trial?
SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a massive, multinational clinical trial involving 17,604 patients across 41 countries. It was designed to answer one question: Does semaglutide reduce the risk of heart attacks, strokes, and cardiovascular death in people with obesity and existing heart disease — but without diabetes?
Participants were 45 years or older with a BMI of 27+ and established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease). They were randomly assigned to receive either semaglutide 2.4 mg weekly or placebo, in addition to standard cardiovascular care. The average follow-up was about 40 months.
The Results
Semaglutide reduced major adverse cardiovascular events (MACE — the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke) by 20% compared to placebo (hazard ratio 0.80). The event rate was 6.5% in the semaglutide group versus 8.0% in the placebo group.
Breaking down the components: semaglutide reduced nonfatal heart attacks, nonfatal strokes, and — in prespecified analyses — heart failure hospitalizations (18% reduction) and all-cause mortality (19% reduction, though the cardiovascular death endpoint alone didn't reach statistical significance).
These benefits were consistent across subgroups regardless of age, sex, BMI, or baseline health status. Patients with a history of heart failure saw particularly strong benefits, with MACE reductions of 31–35% depending on heart failure subtype.
What Changed After SELECT
The FDA expanded Wegovy's approved indication to include cardiovascular risk reduction in adults with established CVD and obesity or overweight. This changed the insurance calculus: even plans that exclude weight loss medications may cover Wegovy when prescribed specifically for cardiovascular risk reduction, because it's now a cardiovascular drug with an obesity indication — not just a weight loss drug.
The American Heart Association, American College of Cardiology, and other major medical organizations updated their guidelines to recommend GLP-1 medications as part of cardiovascular risk management for eligible patients with obesity.
What's Coming Next
The cardiovascular evidence for GLP-1 medications continues to expand. Tirzepatide (Zepbound) cardiovascular outcome trials are ongoing and expected to report in the coming years. Researchers are also studying whether GLP-1 medications can prevent heart disease in patients who don't yet have it (primary prevention), reduce heart failure progression, improve outcomes after cardiac procedures, and protect kidney function in patients with obesity-related kidney disease.
The Wegovy HD (7.2 mg) approval in March 2026 offers a higher-dose option that may provide even greater cardiovascular benefits, though this hasn't been studied in a dedicated CV outcome trial at the higher dose.
The Bottom Line
SELECT proved that semaglutide doesn't just help you lose weight — it helps protect your heart. A 20% reduction in major cardiovascular events is one of the most significant findings in obesity medicine history. It established that treating obesity is cardiovascular prevention, not just cosmetic improvement.
If you have existing heart disease and obesity or overweight, talk to your cardiologist and primary care provider about whether Wegovy is appropriate for you — not just for weight loss, but for heart protection. Insurance coverage may be different when the prescription is written for cardiovascular risk reduction rather than obesity alone.